Steven Branco

Focused on healthcare analytics. #bigdata #healthit #healthcareanalytics #datascience #artificialintelligence #ai. Columbia Business School alum @Columbia_Biz

[Steven Branco @sagustin]

@elonmusk Amazing

[Larry Levitt @larry_levitt]

New government estimates show 92% of people in the U.S. had health coverage in 2022, the highest level ever.

But, that may be as close as we get to universal coverage for some time, since pandemic enrollment protections in Medicaid are now unwinding.

https://t.co/KVnOkCJMQt

[Rick Berke @rickberke]

Quitting alcohol — or even drinking less — reduces risk of oral cavity and esophageal cancer, per new analysis https://t.co/I66CS5M2wg via @statnews @angRchen

[BioWorld @BioWorld]

Top Trends of 2023: EU pharma reform seeks to provide equitable access; threatens data exclusivity, incentives https://t.co/LA9nnMOrDc #biotech #pharma

[JAMA @JAMA_current]

More than 81K people died of drug overdoses in the US June 2019—May 2020, a record-breaking number that @CDCgov suggested is related to the #COVID19 pandemic, largely due to synthetic opioid use (ie, illicit #fentanyl) https://t.co/TyLS9Lqfol @jamahealthforum @jamapsych

[The Lancet Oncology @TheLancetOncol]

Online first: #Endoscopic #surgery compared with intensity-modulated #radiotherapy in resectable locally recurrent #nasopharyngealcarcinoma: a randomised, controlled, phase 3 trial https://t.co/anlkFtrJXw
#HeadNeckCancer

[JAMA Internal Medicine @JAMAInternalMed]

Contents of FDA Refuse-to-File Letters for New Drug Applications and Their Public Disclosure by Applicants https://t.co/PnBqumxjNr #onlinefirst

[Sek Kathiresan MD @skathire]

Point estimate from Phase 3 study:
94% relative risk reduction

Point estimate from real-world data:
94%

Not too shabby, @pfizer @BioNTech_Group 👏🏽👌🏽

[J&J Innovative Medicine @JNJInnovMed]

We’re celebrating #WomenInScience today! Follow along to find out what inspired some of our female scientists to pursue a career in #STEM and how they inspire the next generation of women to do the same.

[FDA Drugs and Biologics @FDADrugs]

FDA’s Office of Pharmaceutical Quality (OPQ) issued their 2020 Annual Report. The report covers their challenges & accomplishments in 2020 as they worked to assure the nation had access to safe, effective, quality medicines during the #COVID19 pandemic. https://t.co/xRoejrTPyh

[STAT @statnews]

Opinion: As the world grapples with a stream of new coronavirus variants, we should not lose sight of the larger implications of naming diseases and the pathogens that cause them. Call them by their scientific names. https://t.co/92SvLRrOtu

[Pharmafocus @Pharmafocus]

Janssen announces positive Phase III results for prostate cancer drug apalutamide https://t.co/WqxGT68EZb

[Pharmafocus @Pharmafocus]

FDA approves Sanofi's Libtayo for advanced basal cell carcinoma https://t.co/tRznWxd1xs

[STAT @statnews]

STAT built its own database by combing through and compiling data from hundreds of documents, including summaries filed by manufacturers to the FDA that outline the intended use and technical specifications of each product. https://t.co/41nytBrTk1

[STAT @statnews]

As the FDA clears a flood of AI tools, missing data raise troubling questions on safety and fairness https://t.co/VHApueDHKI

[STAT @statnews]

U.S. regulators have approved more than 160 medical AI products in recent years based on widely divergent amounts of clinical data and without requiring manufacturers to publicly document testing on patients of different genders, races, and geographies. https://t.co/n6iQ3VKcOh

[Nature Medicine @NatureMedicine]

A prospective, multicenter, case–control clinical trial evaluates the potential of #artificialintelligence for providing accurate bedside #diagnosis of patients with #braintumors https://t.co/lRNzbyT4qe #AI #NMEDClinical @DanOrringerMD

[Merck @Merck]

Today we announce that Ken Frazier, Chairman & CEO, will retire as CEO June 30, 2021. Rob Davis, our current EVP, Global Services & CFO, will become CEO and a member of the board of directors, July 1, 2021. Mr. Frazier will continue as executive chairman. https://t.co/ooNbqEBWz7

[ZS @ZSAssociates]

How can MSLs drive engagement with KOLs? In this white paper, ZS Principal Sunil John shares a data-driven engagement framework to help #pharma companies adapt to the changes in their industry. https://t.co/6PFrdCwrSh

[ZS @ZSAssociates]

How can MSLs drive engagement with KOLs? In this white paper, ZS Principal Sunil John shares a data-driven engagement framework to help #pharma companies adapt to the changes in their industry. https://t.co/6PFrdCwrSh
#medicalaffairs